Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, Tuesday announced positive interim data from the Phase 2 FORWARD-53 study evaluating WVE-N531 in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration, and caused by problem in producing a protein called dystrophin that helps keep muscle cells intact.
In the study, 11 boys amenable to exon 53 skipping are being treated with WVE-N531. Results from the interim analysis of ambulatory boys showed dystrophin expression of 9 percent and mean absolute unadjusted dystrophin expression of 5.5 percent. Eighty nine percent of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5 percent. Further, WVE-N531 was safe and well tolerated.
The company expects to report complete data from the study in the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.